Bayer | Pharmaceuticals

How can we make cancer therapy kinder? 📖 Read our latest article to explore the shift from conventional to precision oncology, aiming for both more effective and kinder medicines. Join us in the quest for a future where patients could experience better quality of life during their treatment. 👇👇👇 #PrecisionOncology #HealthcareInnovation #BayerPrognosis #oncologyinspired #TeamBayer

Get to know our data science rockstar Steffen Vogler who is working in our Radiology R&D team! As a Medical Imaging Specialist he uses AI to decipher and analyze medical images like X-rays or CT scans. Learn more about him and discover how he envisions artificial intelligence promoting healthcare equity across the globe 👇 #DataScienceRockstars #TeamBayer #InnovationInHealthcare #Radiology #AI

I had the pleasure of sitting down again with Dan Vahdat from Huma to get a first-hand view of the Huma Cloud Platform and an update on Huma’s progress within Bayer. Huma has been a bright spot in our Leaps by Bayer portfolio - they have continuously grown and delivered value in a competitive and challenging digital health market. The Huma Cloud Platform, launched last week, enables pharmaceutical companies to build and launch patient-facing digital apps in days, not years. Huma’s unique enterprise platform approach means that different teams can leverage the same software tools to configure patient apps for any disease area at any point in the medicine lifecycle, from the R&D phase through post-launch. Pharmaceutical companies need more efficient, consistent, and cost-effective means to build digital health solutions and minimize spending on duplicative efforts that can’t scale - Huma Cloud Platform can deliver this. I look forward to seeing how Dan and the Huma team continue to change the world of healthcare and life sciences by accelerating the adoption of digital & AI solutions across the board.

+++ #News +++ Vividion Therapeutics, Inc., a wholly owned and independently operating subsidiary of Bayer, plans to expand in San Diego with a new global Research and Development Center and corporate headquarters. #TeamBayer continues to drive growth in the biotech industry within one of the most innovative life science hubs in the United States. Learn more: http://spr.ly/6049cBiyJ #HealthForAll #HungerForNone

"My mom's experience with lung cancer showed me the incredible strength of patients. Now, at Bayer, I'm empowered to champion patients’ needs.” Peter Said, Patient Engagement Lead for Asia-Pacific at Bayer, shares how his mother’s lung cancer diagnosis fueled his passion for patient advocacy at Bayer. We are proud to have Peter on board, making patients' voices a priority in all we do at #TeamBayer.

+++ #NEWS +++ We are pleased to announce topline results from a Phase III trial in men with metastatic hormone-sensitive #ProstateCancer (mHSPC). Learn more: https://lnkd.in/ekY-krjA #TeamBayer #OncologyInspired

AI seems to hold a lot of different potentials. Today, we asked some of our dear #radiology colleagues from #TeamBayer, what they appreciate about #AI. Listen to Oisín Butler, Franziska Lobig, Mike McDermott and Shruti Panwalkar sharing their perspectives. Now, let us know: What do YOU appreciate about AI? #AIAppreciationDay #BayerInRadiology #SeeThePossibleCreateTheFuture

#Team Bayer is committed to advancing science by investing in partnerships and collaborations for research. To foster awareness and understanding of the need for safer antithrombotic therapies, we have joined industry partners in support of an educational initiative announced by the leading international society International Society on Thrombosis and Haemostasis (ISTH). We are dedicated to exploring potential new options in stroke prevention to address areas of greatest unmet need.

Having the opportunity to connect with others working in the cell and gen therapy space is always a highlight in my calendar. This week I was looking forward to the #ISSCR2024 meeting in Hamburg, which is gathering more than 4000 champions from the #StemCell community. And so far I have not been disappointed. Our workshop on “Advances in in the treatment of #ParkinsonsDisease : the possibilities of cell therapy” on Wednesday was a great success ! Thank you, #VivianTabar, and #DavidPedrosa for sharing your excitement about the fascinating breakthrough data. It’s highly encouraging for both the #Parkinson patients and the cell community! In addition to that, there are so many other promising developments I learned about. Thank you, #TeamBayer, and #Bluerockers for engaging in the scientific exchange and driving innovation for patients !

#TeamBayer is proud to announce our collaboration with Microsoft and healthcare professionals from across our region EMEA I. Under the umbrella of #GenAiCare, we are dedicated to accelerating the responsible use of #GenAI applications in healthcare for better patient outcomes. A special thanks to our partners at Microsoft and all the dedicated healthcare professionals involved. Stay tuned as we embark on our first initiatives to make a meaningful impact. Bayer is transforming healthcare by harnessing cutting-edge artificial intelligence (AI) technologies. AI unlocks a wealth of insights and efficiencies that help support physicians and improve treatment options and outcomes for patients. Read more: https://lnkd.in/eBcHFtqh